Corporate Governance

Quality Assistance is a private, independent company founded in 1982 by Philippe Draux and Philippe De Raeve. For over 40 years, we have established ourselves as a leader in analytical sciences, holding a unique position in the pharmaceutical market. All our laboratories are located on a single site, which promotes synergy and ensures the highest quality standards.

Our team of 280 highly qualified professionals is committed to delivering reliable and compliant analytical services to our clients. Quality Assistance’s governance is built on principles of transparency, responsibility and ethics ensuring sustainable growth and trust among our stakeholders.

Governance Structure

Quality Assistance’s governance is overseen by a Board of Directors, which defines strategic orientations and best practices.

Board of Directors:

  • QUALITY LIFE INVEST S.A., represented by Philippe Draux (Executive Chairman)
  • CMHC SRL, represented by Carl Mestdagh (Vice-Chairman)
  • Nathalie Draux (CEO)
  • Marie-Line Colassin
  • SPARAXIS S.A., represented by Géry Lefebvre
  • BNP PARIBAS FORTIS PRIVATE EQUITY MANAGEMENT S.A., represented by Patricia Terry

Proven Financial Strength

With over 40 years of experience, our company has consistently demonstrated financial resilience and stability. Through disciplined management and a long-term vision, we have maintained a solid financial foundation, ensuring sustainable growth and reliable performance for all stakeholders.

More about our Shareholding

Specialised Committees

Scientific Advisory Board

The Scientific Advisory Board plays an essential role in ensuring our scientific and technological strategy aligns with the evolving needs of our clients and regulatory expectations. Its mission is to:

  • Identify and prioritise emerging therapeutic modalities where Quality Assistance should invest to develop analytical capabilities, leveraging its scientific expertise to support pharmaceutical companies.
  • Guide strategic investments in analytical techniques and technologies to anticipate future trends and accelerate innovation.

    Learn more about our SAB

Data Governance Board

Although data management has always been a top priority at Quality Assistance, we formalised this commitment in 2025 by creating a dedicated Data Governance Board. This Board ensures the integrity, quality, security, availability, and compliance of all data produced, processed, and stored within the company. It oversees strategic decisions, risk management, and the implementation of systems supporting these missions, while promoting traceability and treating data as a valuable corporate asset. To reinforce this approach, we are supported by an external Chief Information Security Officer (CISO), who provides expertise in cybersecurity and regulatory compliance. Through regular reviews and audits, the Board guarantees transparency and accountability in all data-related activities.

Our commitment to public health

At Quality Assistance, we stand by a clear conviction: public health is a shared responsibility. Since 2006, eight guiding principles have shaped the way we operate, ensuring the reliability of our services and the transparency of our relationships with clients, partners, and regulatory authorities.

  • Recruit personnel with appropriate qualifications
  • Organise an in-service personnel training programme
  • Periodically assess the level of competence acquired by the personnel
  • Keep the personnel informed of evolution in the sector via the scientific, technological and regulatory surveillance carried out by the R&D and Innovation department

  • Respect the rules set out in the Site Master File
  • Respect the organisational and technical procedures drawn up and reviewed periodically
  • Respect the pharmaceutical sector quality standards: GMP, GLP, GCLP and GCP
  • Keep track of national and international regulations applicable to the development, registration and manufacturing of medicinal products

  • Reliably evaluate the work requested and the overall workload at any time
  • Use appropriate tools to ensure transparent planning for each person involved in the project

  • Establish efficient communication
  • Ensure regular contacts, managed by a Project Leader, between the personnel in charge of the project and the client, especially in the case of deviations from an approved protocol, modifications to planning and unexpected results
  • Computerised traceability of all contacts, internal and external, business and technical, for each project

  • Inform the personnel of, and training them in, the industrial risks specific to our activity via a Biosafety Committee and a Committee for the Protection of Workers
  • Ensure the personnel has thorough knowledge of the Material Safety Data Sheets for the products handled
  • Limit access to client documents, samples and products to authorised people
  • Protect electronic data via a dedicated restricted access server room, daily backups and a secured network

  • Give clients a formal commitment to respect confidentiality for any projects outsourced to them
  • Ensure the accountability of the personnel in their involvement in the process of development of medicinal products which gives them access to confidential data

  • Give appropriate information on, and training in, the environmental risks linked to our sector of activity
  • Use natural resources and energy efficiently and rationally
  • Manage disposal of solid and liquid waste appropriately

  • Behave professionally, responsibly and with integrity, respecting the laws and regulations in force in the context of our activity
  • Ensure the absence and refusal of any requests or personal benefits which could influence the assignment and/or performance of work
  • Respect appropriate, transparent, impartial procedures in the selection of suppliers and providers
  • Keep shareholders and investors informed of the evolution of the company